Journal of the Korean Association of Oral and Maxillofacial Surgeons

  • 제36권4호
  • /
  • Pages.291-302
  • /
  • 2010
  • /
  • 2234-7550(pISSN)
  • /
  • 2234-5930(eISSN)
대한구강악안면외과학회 (The Korean Association of Oral and Maxillofacial Surgeons)
권호 표지
DOI QR코드

DOI QR Code

비스포스포네이트 관련 악골괴사에 대한 연구: 증례보고 및 문헌문석

Study on bisphosphonate-related osteonecrosis of the jaw (BRONJ): case report and literature review

  • 김여갑 (경희대학교 치의학전문대학원 부속병원 구강악안면외과) ;
  • 이백수 (경희대학교 치의학전문대학원 부속병원 구강악안면외과) ;
  • 권용대 (경희대학교 치의학전문대학원 부속병원 구강악안면외과) ;
  • 서준호 (경희대학교 치의학전문대학원 부속병원 구강악안면외과) ;
  • 진상미
  • Kim, Yeo-Gab (Department of Oral and Maxillofacial Surgery, School of Dentistry, Kyung Hee University) ;
  • Lee, Baek-Soo (Department of Oral and Maxillofacial Surgery, School of Dentistry, Kyung Hee University) ;
  • Kwon, Yong-Dae (Department of Oral and Maxillofacial Surgery, School of Dentistry, Kyung Hee University) ;
  • Suh, Joon-Ho (Department of Oral and Maxillofacial Surgery, School of Dentistry, Kyung Hee University) ;
  • Jeen, Sang-Mi (School of Dentistry, Kyung Hee University)
  • 투고 : 2010.05.06
  • 심사 : 2010.07.27
  • 발행 : 2010.08.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a side effect of Bisphosphonates (BPs) use. These days, oral bisphosphonates are normally prescribed to treat osteoporosis. Intravenous BPs are used extensively to treat osteolytic bone lesions related to multiplemyeloma and bone metastasis of solid cancers, breast cancer or prostate cancer. As the prescription of BPs is universalized and the number of people treated with BPs is increasing, an accurate understanding and proper management of BRONJ are required. The aim of this study was to improve the clinicians' understanding of BRONJ by reviewing the literature. To achieve this, this paper introduces case reports as well as the current concept of BRONJ based on the 2009 updates by American Association of Oral and Maxillofacial (AAOMS) including the definition, epidemiology, etiology, diagnosis, treatment and prevention of BRONJ.

키워드

참고문헌

  1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003;61:1115-7. https://doi.org/10.1016/S0278-2391(03)00720-1
  2. Marx RE, Sawatari Y, Fortin M, Broumand V. Biphosphonateinduced exposed bone (osteonecrosis/ostoepetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 2005;63:1567-75. https://doi.org/10.1016/j.joms.2005.07.010
  3. Advisory Task Force on Bisphosphonate-Related Ostenonecrosis of the Jaws, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369-76. https://doi.org/10.1016/j.joms.2006.11.003
  4. Kwon YD, Yoon BW, Walter C. Bisphosphonate, is it an emerging risk factor in oral surgery? J Korean Assoc Maxillofac Plast Reconstr Surg 2007;29:456-62.
  5. Park YD, Kim YR, Kim DY, Chung YS, Lee JK, Kim YG, et al. Awareness of Korean dentists on bisphosphonate related osteonecrosis of the jaws: preliminary report. J Korean Assoc Oral Maxillofac Surg 2009;35:153-7.
  6. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009;67(5 Suppl):2-12. https://doi.org/10.1016/S0278-2391(09)01877-1
  7. The Korean Endocrine Society, the Korean Society of Bone Metabolism, the Korean Society of Osteoporosis, the Korean Association of Oral and Maxillofacial Surgeons. Bisphosphonate related osteonecrosis of the jaw (BRONJ): position statement of Korea. J Korean Endocr Soc 2009;24:227-30. https://doi.org/10.3803/jkes.2009.24.4.227
  8. Francis MD, Russell RG, Fleisch H. Diphosphonate inhibit formation of calcium phosphate crystals in vitro and pathological calcifications in vivo. Science 1969;165:1264-6. https://doi.org/10.1126/science.165.3899.1264
  9. van Beek E, Pieterman E, Cohen L, Lo ¨wik C, Papapoulos S. Farnesyl pyrophosphate synthase is the molecular target of nitrogen containing bisphosphonates. Biochem Biophys Res Commun 1999;264:108-11. https://doi.org/10.1006/bbrc.1999.1499
  10. Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J Dent Res 2007;86:1022-33. https://doi.org/10.1177/154405910708601102
  11. Vaananen HK, Zhao H, Mulari M, Halleen JM. The cell biology of osteoclast function. J Cell Sci 2000;113:377-81.
  12. Fantasia JE. Bisphosphonates-what the dentist needs to know: practical consideration. J Oral Maxillofac Surg 2009;67(5 Suppl):53-60.
  13. Hillner BE, Ingle JN, Berenson JR, Janjan NA, Albain KS, Lipton A, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000;18:1378-91. https://doi.org/10.1200/JCO.2000.18.6.1378
  14. Mehrotra B. Bisphosphonates-role in cancer therapies. J Oral Maxillofac Surg 2009;67(5 Suppl):19-26. https://doi.org/10.1016/S0278-2391(09)01878-3
  15. Landesberg R, Eisig S, Fennoy I, Siris E. alternative indications for bisphosphonate therapy. J Oral Maxillofac Surg 2009;67(5 Suppl):27-34.
  16. Allen MR, Burr DB. The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg 2009;67(5 Suppl):61-70.
  17. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 2007;1117:209-57. https://doi.org/10.1196/annals.1402.089
  18. Garetto LP, Chen J, Parr JA, Roberts WE. Remodeling dynamics of bone supporting rigidly fixed titanium implants: a histomorphometric comparison in four species including humans. Implant Dent 1995;4:235-43. https://doi.org/10.1097/00008505-199500440-00002
  19. Han ZH, Palnitkar S, Rao DS, Nelson D, Parfitt AM. Effects of ethnicity and age or menopause on the remodeling and turnover of iliac bone: implications for mechanism of bone loss. J Bone Miner Res 1997;12:498-508. https://doi.org/10.1359/jbmr.1997.12.4.498
  20. Allen MR, Burr DB. Mandible matrix necrosis in beagle dogs after 3 years of daily oral bisphosphonate treatment. J Oral Maxillofac Surg 2008;66:987-94. https://doi.org/10.1016/j.joms.2008.01.038
  21. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007;22:1832-41. https://doi.org/10.1359/jbmr.070809
  22. Harper RP, Fung E. Resolution of bisphosphonate-associated osteonecosis of the mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-34)]. J Oral Maxillofac Surg 2007;65:573-80. https://doi.org/10.1016/j.joms.2006.10.076
  23. Lau AN, Ali SH, Adachi JD. Resolution of osteonecosis of the jaw after teriparatide [recombinant human PTH (1-34)] therapy. Osteoporos Int 2008;19 Suppl 1:S80.
  24. Wang HL, Weber D, McCauley LK. Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report. J Periodontol 2007;78:584-94. https://doi.org/10.1902/jop.2007.060239
  25. Li C, Mori S, Li J, Kaji Y, Akiyama T, Kawanishi J, et al. Longterm effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. J Bone Miner Res 2001;16:429-36. https://doi.org/10.1359/jbmr.2001.16.3.429
  26. Peter CP, Cook WO, Nunamaker DM, Provost MT, Seedor JG, Rodan GA. Effect of alendronate on fracture healing and bone remodeling in dogs. J Orthop Res 1996;14:74-9. https://doi.org/10.1002/jor.1100140113
  27. Frost HM. In vivo osteocyte death. J Bone Joint Surg Am 1960;42A:138-43.
  28. Roelofs AJ, Coxon FP, Ebetino FH, Bala JF, Kashemirov BA, McKenna CE, et al. Use of a fluorescent analogue of risedronate to study localisation and cellular uptake of bisphosphonates in vivo. Bone 2008;42 Suppl 1:S85.
  29. Guise TA. Antitumor effects of bisphosphonates: promising preclinical evidence. Cancer Treat Rev 2008;34 Suppl 1:S19-24. https://doi.org/10.1016/j.ctrv.2008.03.006
  30. Lipton A. Emerging role of bisphosphonates in the clinic-antitumor activity and prevention of metastasis to bone. Cancer Treat Rev 2008;34 Suppl 1:S25-30. https://doi.org/10.1016/j.ctrv.2008.03.008
  31. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 2004;62:527-34. https://doi.org/10.1016/j.joms.2004.02.004
  32. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-61. https://doi.org/10.1124/jpet.102.035295
  33. Estilo CL, Fornier M, Farooki A, Carlson D, Bohle G 3rd, Huryn JM. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008;26:4037-8. https://doi.org/10.1200/JCO.2007.15.5424
  34. Somerman MJ, McCauley LK. Bisphosphonates: sacrificing the jaw to save the skeleton? Bonekey Osteovision 2006;3:12-8.
  35. Lurie AG, Matteson SR. 99 M/Tc-diphosphonate bone imaging and uptake in healing rat extraction sockets. J Nucl Med 1976;17:688-92.
  36. McDougall IR. Skeletal scintigraphy. West J Med 1979;130:503-14.
  37. Hellstein JW, Marek CL. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is this phossy jaw of the 21st century? J Oral Maxillofac Surg 2005;63:682-9. https://doi.org/10.1016/j.joms.2005.01.010
  38. Hansen T, Kunkel M, Springer E, Walter C, Weber A, Siegel E, et al. Actinomycosis of the jaws-histopathological study of 45 patients shows significant involvement in bisphosphonate-associated osteonecrosis and infected osteoradionecrosis. Virchows Arch 2007;451:1009-17. https://doi.org/10.1007/s00428-007-0516-2
  39. Khamaisi M, Regev E, Yarom N, Avni B, Leitersdorf E, Raz I, et al. Possible association between diabetes and bisphosphonate-related jaw osteonecrosis. J Clin Endocrinol Metab 2007;92:1172-5. https://doi.org/10.1210/jc.2006-2036
  40. Wessel JH, Dodson TB, Zavras AI. Zoledronate, smoking and obesity are strong risk factors for osteonecrosis of the jaw: a case-control study. J Oral Maxillofac Surg 2008;66:625-31. https://doi.org/10.1016/j.joms.2007.11.032
  41. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005;23:8580-7. https://doi.org/10.1200/JCO.2005.02.8670
  42. Hoff AO, Toth BB, Altundag K, Guarneri V, Adamus A, Nooka AK, et al. Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy. ASCO Annual Meeting Proceedings (postmeeting edition). J Clin Oncol 2006;24(18 Suppl):8528.
  43. Durie BG, Katz M, Crowley J. Osteonecrosis of the jaws and bisphosphonates. N Engl J Med 2005;353:99-102. https://doi.org/10.1056/NEJM200507073530120
  44. -Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945-52. https://doi.org/10.1200/JCO.2005.04.2465
  45. Sarasquete ME, Garcl'a-Sanz R, Marl'n L, Alcoceba M, Chillo'n MC, Balanzategui A, et al. Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 2008;112:2709-12. https://doi.org/10.1182/blood-2008-04-147884
  46. Krane SM. Death and taxes: glucocorticoids and Bone Cell Apoptosis. BoneKEy-Osteovision 2001;1:2001019.
  47. Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 2007;86:1013-21. https://doi.org/10.1177/154405910708601101
  48. Ruggiero SL, Fantasia J, Carlson E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2006;102:433-41. https://doi.org/10.1016/j.tripleo.2006.06.004
  49. Arce K, Assael LA, Weissman JL, Markiewicz MR. Imagind findings in bisphosphonate-related osteonecrosis of jaws. J Oral Maxillofac Surg 2009;67(5 Suppl):75-84.
  50. Raje N, Woo SB, Hande K, Yap JT, Richardson PG, Vallet S, et al. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res 2008;14:2387-95. https://doi.org/10.1158/1078-0432.CCR-07-1430
  51. Marx RE, Cillo JE Jr, Ulloa JJ. Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 2007;65:2397-410. https://doi.org/10.1016/j.joms.2007.08.003
  52. Kunchur R, Need A, Hughes T. Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws. J Oral Maxillofac Surg 2010 68(2):487-8. https://doi.org/10.1016/j.joms.2009.07.088
  53. Kos M, Kuebler JF, Luczak K, Engelke W. Bisphosphonate-related osteonecrosis of the jaws: a review of 34 cases and evaluation of risk. J Craniomaxillofac Surg 2010;38:255-9. https://doi.org/10.1016/j.jcms.2009.06.005
  54. Madrid C, Sanz M. What impact do systemically administrated bisphosphonates have on oral implant therapy? A systematic review. Clin Oral Implants Res 2009;20 Suppl 4:87-95.

피인용 문헌

  1. Associated risk factors and prevention of bisphosphonate-induced osteonecrosis of the jaw : vol.4, pp.2, 2010, https://doi.org/10.1097/01.omx.0000428132.28641.c9
  2. Bisphosphonate Related Osteonecrosis of the Jaw: An Update vol.13, pp.4, 2010, https://doi.org/10.1007/s12663-013-0564-x